Purpose: Metastatic renal cancer is associated with a poor prognosis. Recent advances in immunotherapy for this problem have rekindled interest in cytoreductive nephrectomy. We report a combined analysis of 2 prospective randomized trials that used an identical study protocol.
Metastatic renal cancer is associated with a poor prognosis with a median survival of approximately 7 months. In the past several factors contributed to the controversy regarding the role of cytoreductive nephrectomy (Nephr) in this setting. Renal cancer has proved to be extremely resistant to the chemotherapeutic agents tested. Recent nonrandomized studies demonstrated a consistent, albeit low, response rate to biological response modification agents and suggested that removal of the primary tumor is associated with increased survival. Until recently no studies have controlled for the timing of nephrectomy. Two recently reported prospective, randomized trials performed by the Southwest Oncology Group (SWOG 8949) and the European Organization for the Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC 30947) used an identical protocol design in evaluating cytoreductive nephrectomy plus interferon (IFN) ␣-2b (Intron-A, Schering-Plough, Kenilworth, New Jersey) vs interferon-2b alone. 1, 2 
MATERIALS AND METHODS
A total of 331 patients (246 in SWOG 8949 and 85 in EORTC 30947) were randomized on these 2 trials. 1, 2 Eligibility for the 2 trials was identical, in that patients with any T, any N and any M1 disease were eligible if believed to have a primary tumor amenable to surgical extirpation and an Eastern Cooperative Oncology Group performance status of 0 or 1, and had received no prior chemotherapy, hormonal therapy, radiation therapy or treatment with a biological response modifying agent. In addition to evidence of distant metastatic disease, patients were allowed to have evidence of regional lymph node involvement and/or inferior vena caval thrombus if the thrombus was located below the hepatic veins. All patients had to have a pre-randomization biopsy (primary or metastatic site), adequate liver function (bilirubin less than 3 mg%), adequate renal function (creatinine less than 3 mg%) and no prior malignancy unless there was no evidence of recurrence for at least 5 years (more recent skin or in situ cervical cancer was allowed).
Nephrectomy could be accomplished by any route but it had to be accomplished outside of Gerota's fascia and had to occur within 4 weeks of registration. Regional lymphadenectomy was not required but the surgeon had to report whether lymph nodes were resected. Interferon ␣-2b was given at a dose of 5 million U/m 2 on Monday, Wednesday and Friday of each week, which was continued until progression. An induction dose regimen was used (1.25 MU/m 2 on day Ϫ3, 2.5 MU/m 2 on day Ϫ2 and 3.75 MU/m 2 on day Ϫ1) and standard adjustments for toxicity based on these levels were also used. Patients randomized to no surgery were required to start interferon within 1 working day, while patients randomized to nephrectomy were to start interferon 1 month after surgery but preferably within 14 days. Patients could stop treatment for progressive disease, unacceptable toxicity or withdrawal of consent. The end points of the 2 studies were primary-survival and secondary-response rate. Measurable, evaluable and nonevaluable (pleural effusion, ascites or laboratory abnormalities) metastatic diseases were allowed.
Statistical considerations for the SWOG study assumed a median survival of 1 year for patients treated with interferon ␣-2b alone. The trial was designed to detect a 50% improvement in median survival and a 15% improvement in response rate with a type I error of 0.05 and a power of 0.85. The goal of the EORTC trial was to enter an additional 80 patients, which could be used in an independent assessment of the value of nephrectomy and in a combined analysis with the SWOG trial. All eligible patients from each trial were included in the analysis based on intent to treat criteria. Survival duration was estimated using the Kaplan-Meier technique and compared using the 2-sided log rank test with retrospective stratification for study. All eligible patients with measurable disease were included in the response rate analysis.
RESULTS
Overall 331 patients were randomized to the 2 trials. Seven patients (2.1%) were classified as ineligible because of incorrect pathological findings. Of 161 patients 20 (12.4%) in the nephrectomy arm did not receive surgery, whereas 3 of 163 (1.8%) in the interferon only arm and 9 (5.6%) in the nephrectomy arm did not receive immunotherapy. The table lists the characteristics of eligible patients. The treatment arms were well balanced except for a slight imbalance in performance status (performance status 1 in 58.9% of interferon only treated patients compared to 46.6% in nephrectomy plus interferon treated patients).
Survival. Overall median survival was 13.6 months (95% CI 9.7 to 17.4) for nephrectomy plus interferon vs 7.8 months (95% CI 5.9 to 9.7) for interferon alone (HR 0.69, 95% CI 0.55 to 0.87, p ϭ 0.002, fig. 1 ). It represents a 31% decrease in the risk of death in the surgery arm. The Kaplan-Meier estimate of 1-year survival was 51.9% for the nephrectomy arm vs 37.1% for the interferon only arm. This combined analysis was performed using intent to treat principles. It is true that 12% of the patients randomized to nephrectomy and interferon did not undergo surgery and another 5.6% in this arm did not receive interferon. Excluding those patients from analysis would have slightly increased the statistical significance of the treatment comparison. However, we strongly believe that these data should be analyzed using intent to treat principles because the exclusion of patients not able to undergo nephrectomy from the nephrectomy arm would result in a biased comparison of all patients undergoing interferon treatment compared to only those in the nephrectomy fit enough to undergo the operation. Figure 1 shows unadjusted survival curves for the 2 treatment regimens. Figure 2 shows the forest plot of the treatment comparison adjusted by study. Patients with a performance status of 0 had significantly longer survival than patients with a performance status of 1 (p Ͻ0.0001). Neither site of metastases nor disease measurability had prognostic importance. Retrospective stratification for performance status, site of metastases and disease measurability did not change the overall conclusions since there was no evidence of a difference in the size of the treatment effect according to the levels of any of these factors (figs. 3 to 5).
Response to treatment. Response rates varied considerably between the 2 trials analyzed, namely 3.2% for all eligible patients with measurable disease in the SWOG trial and 16% in the EORTC trial. In the 253 patients in the trials with measurable disease there was a 6.9% objective response rate (3 complete plus 6 partial responses) in the nephrectomy plus interferon group vs a 5.7% response rate (2 complete plus 4 partial responses) in the interferon group (p ϭ 0.60).
Surgical complications and side effects. Complications of surgery were less than those reported in older series of cytoreductive nephrectomy. Analysis showed that 108 of 141 patients (76.6%) undergoing nephrectomy had no surgical complications. Two surgical deaths (1.4%) occurred. Grade IV complications occurred in 5.2% of cases, including cardiac events in 3, infections in 4, severe hypotension in 1 and cerebellar syndrome in 1.
Complications of interferon therapy were evaluable in 285 patients. Median time to the initiation of interferon treatment after nephrectomy was 19 days (see table) . One patient (0.3%) died of cardiovascular toxicity in the interferon only group. In the SWOG trial grade 4 toxicity occurred in 10 patients who received nephrectomy and in 13 who received only interferon. Dose modification was necessary in 44% of nephrectomized cases compared to 22% of those receiving interferon alone. 1 This trend was also seen in the EORTC trial, where the cause but not the degree of dose reduction was also recorded. 2 Quality of life data were not recorded in either trial. A review of SWOG data revealed a mean hospitalization of 8.2 days for patients undergoing nephrectomy. These data were not available for the EORTC trial.
DISCUSSION
This combined analysis compiles data from the only prospective, randomized trials of cytoreductive nephrectomy accomplished to date. 1 apy may be beneficial in patients with metastatic renal cancer. [3] [4] [5] [6] [7] Unfortunately these single institution trials have not always controlled for the timing of nephrectomy and have not provided a control group of patients for comparison. This combined analysis is particularly valuable because the 2 published studies used an identical protocol, including identical eligibility, treatment and followup criteria. In fact, the protocol in the EORTC trial was taken directly from one in use in the SWOG 8949 trial. In the setting of patients being treated for metastatic renal cancer with interferon ␣-2b this combined analysis shows that cytoreductive nephrectomy results in a statistically improved overall survival (31% decrease in the death rate in the surgery group). Because it is based on more patients and deaths, the combined analysis provides a more accurate estimate of the size of the treatment difference and a more convincing result than either trial alone. For example, after adjusting for performance status, the survival difference in the SWOG study was not statistically significant. Based on this combined analysis the difference is now significant. Prognostic factor analysis was also done, showing the prognostic importance of performance status but not the site of metastases or disease measurability. Therefore, these data support previous data suggesting the importance of performance status as well as adequate cardiac and pulmonary status. 8 -10 It is also important to note that this analysis confirms that a homogeneous survival advantage is maintained across the levels of all 3 stratification variables (performance status, site of metastases and disease measurability). Although the data strongly suggest that the greatest degree of absolute benefit from cytoreductive nephrectomy is achieved in patients with a performance status of 0, the combined data also supports the contention that nephrectomy is recommended in all patients fit enough to undergo the procedure.
Major arguments against the role of cytoreductive nephrectomy have been the potential morbidity and mortality of surgery, the fact that many patients may not be able to proceed to biological response modification therapy after nephrectomy and the fact that most patients do not respond to biological response modification therapy re- gardless and, as such, nephrectomy should be reserved for those already demonstrating a response to such therapy. This combined analysis directly addresses the first 2 concerns. Although series from the 1970s and 1980s demonstrated perioperative mortality rates of 6% to 11% in this setting, most recent reports have demonstrated a marked decrease in perioperative deaths. [11] [12] [13] [14] In this combined analysis 2 deaths (1.5% of patients undergoing nephrectomy) were seen. In addition, surgical complications occurred in only 20% of patients and were graded as severe (grade IV) in only 5%. Historical series have demonstrated a wide variability in the number of patients able to proceed to biological response modification therapy after nephrectomy, ranging from 0% to 50%. 10 -14 In this analysis only 5.6% of patients did not proceed to interferon therapy for medical reasons. Recent reports have described the possibility of laparoscopic cytoreductive nephrectomy in this patient population and have suggested that it is possible in the majority of such patients despite a large tumor burden to remove the primary lesion with less morbidity, a shorter hospital stay and earlier institution of adjuvant therapy. 14 Although it represents a 31% reduction in the risk of death compared to the control group, it is certainly not the degree of advantage that one would hope for. Some have suggested that an interpretation of these data is that interferon may have limited value in the treatment of metastatic renal cancer. This question was not addressed by either of these trials and it cannot be inferred from this combined analysis. However, a recent report from the University of California-Los Angeles group compared their experience with interleukin-2 based adjuvant immunotherapy after cytoreductive nephrectomy and found an overall survival of 16.7 months. 16 They compared their data historically to our SWOG data and found a doubling of survival compared to SWOG interferon only cases and 30% improvement compared to the SWOG nephrectomy plus interferon cases. Survival at 5 years was 19.6% in the University of California-Los Angeles series compared to 10% for the SWOG nephrectomy plus interferon cases. Although these data are limited by the historical nature of the comparison, they suggest the possibility that more aggressive, nonspecific immunotherapy or new modalities of specific immunological intervention 17 may further enhance the survival advantage seen with cytoreduction.
